PRESS RELEASE
Uppsala
July 15, 2009

Panel Meeting Durolane™ August 19th 2009

Q-Med's Premarket Approval (PMA) application for Durolane™ in the US will be discussed on August 19th 2009, at a public meeting of the FDA's Orthopaedic and Rehabilitation Devices Advisory Committee. The panel is expected to consider the clinical trial results Q-Med submitted to support the approval and labeling of Durolane, a single dose product indicated for the treatment of pain caused by osteoarthritis of the knee.

Queries should be addressed to:
Alexander Kotsinas, Vice President and CFO
Tel: +46 (0)73-500 1111

Per Langö, Senior Director Corporate Development
Tel: +46 (0)73-387 15 21

Cindy Wong, Chief Medical officer and Head of Medical Affairs
Tel: +46 (0)73-387 14 50

__Q-Med AB__ is a medical device company. The company develops, manufactures, markets, and sells primarily medical implants. The majority of the products are based on the company's patented technology, __NASHA™__, for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: __Restylane®__ for filling lines and folds, contouring and creating volume in the face, __Macrolane™__ for body contouring, __Durolane™__ for the treatment of osteoarthritis of the hip and knee joints, __Deflux®__ for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, and __Solesta™__ for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q-Med today has about 650 coworkers, with approximately 400 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the NASDAQ OMX Nordic.
